Last reviewed · How we verify
Epinephrine 1:200,000
Epinephrine 1:200,000, marketed by Rio de Janeiro State University, holds a position in the epinephrine market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and indication, which are critical for emergency treatments. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Epinephrine 1:200,000 |
|---|---|
| Sponsor | Rio de Janeiro State University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Pain Relief Between Two Methods of Freezing Injections in Children Having Their Appendix Removed (NA)
- Laparoscopically Guided Rectus Sheath Block in Pediatric Appendicitis (PHASE2)
- Erector Spinae Plane Block For Analgesia Following Video-Assisted Thoracoscopic Surgery (NA)
- Bupivacaine Versus Lidocaine Infiltration for Postoperative Pain in Thyroid Surgery (PHASE2)
- Rhomboid Intercostal and Sub-Serratus Block for Improving Pulmonary Function and Pain in Patients With Fracture Ribs (NA)
- Effect of Local Anaesthetic Volume on Axillary Brachial Plexus Block Duration (NA)
- Transversus Abdominis Plane Block in Children Undergoing Ostomy Surgery (NA)
- Transversus Abdominis Plane Block in Children Undergoing Open Pyeloplasty Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epinephrine 1:200,000 CI brief — competitive landscape report
- Epinephrine 1:200,000 updates RSS · CI watch RSS
- Rio de Janeiro State University portfolio CI